4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform - Seite 2
Therapeutic Vector Evolution combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Using its proprietary Therapeutic Vector Evolution platform, to date 4DMT has generated an industry-leading 40 distinct capsid libraries, conducted more than 15 vector selections in non-human primates, and has filed patent applications on over 300 novel AAV vectors. Three of these proprietary vectors were used in clinical and/or IND product candidates in ophthalmology (4D-150, 4D-125, 4D-110), cardiology (4D-310) and lung (4D-710). Through these 15 vector selections, 4DMT has generated numerous industry leading and expansive datasets relating to capsid biodistribution and delivery to targeted tissues through routine routes of administration, efficient transduction of target cells, and/or resistance to neutralizing antibodies. The application of machine learning to 4DMT’s Therapeutic Vector Evolution and its datasets represents an opportunity to leverage an enabling technology to invent new vectors for use in targeted gene therapy products.
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.